Reference : Info-congres. Prevention du diabete de type 2 chez le sujet obese: premiers resultats...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Info-congres. Prevention du diabete de type 2 chez le sujet obese: premiers resultats avec l'orlistat dans l'etude XENDOS.
[en] Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Adult ; Anti-Obesity Agents/pharmacology ; Cardiovascular Diseases/etiology/prevention & control ; Diabetes Mellitus, Type 2/prevention & control ; Double-Blind Method ; Female ; Glucose Tolerance Test ; Humans ; Lactones/pharmacology ; Life Style ; Male ; Middle Aged ; Multicenter Studies as Topic ; Obesity/complications ; Placebos ; Randomized Controlled Trials as Topic ; Risk Factors ; Weight Loss
[en] The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in the prevention of Diabetes in Obese Subjects) is a multicentre, randomised, double-blind, placebo-controlled, parallel-group prospective study performed in Sweden over a period of 4 years. The aim of XENDOS was to investigate the use of a weight loss agent (orlistat, Xenical) compared with lifestyle changes for the prevention of type 2 diabetes in obese patients (body mass index > or = 30 kg/m2). Weight loss was greater in the orlistat group (-6.9 kg; n = 1.640) than in the placebo group (-4.1 kg; n = 1.637; p < 0.001). Such a difference in weight reduction was sufficient to significantly reduce the cumulative incidence of type 2 diabetes (6.2% versus 9.0%; p = 0.0032; relative risk reduction of 37.3%). The difference was especially remarkable in obese patients with impaired glucose tolerance (21% of the cohort), with a reduction of conversion to diabetes from 28.8% in the placebo group to 18.8% in the orlistat group (p < 0.005) and a number needed to treat to avoid one event of 11 only. Significant and sustained reductions in cardiovascular risk factors such as arterial blood pressure and lipid levels were also observed in the orlistat group as compared to the placebo group. XENDOS is the first study demonstrating that an antiobesity agent, like orlistat, is able to reduce the progression to diabetes in obese subjects as compared with lifestyle changes alone.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200209_12.pdfNo commentaryPublisher postprint444.22 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.